Literature DB >> 35626368

Variations in Biochemical Values under Stress in Children with SARS-CoV-2 Infection.

Alina Belu1,2,3, Laura Mihaela Trandafir4, Elena Țarcă5, Elena Cojocaru6, Otilia Frăsinariu4, Magdalena Stârcea4, Mihaela Moscalu7, Razvan Calin Tiutiuca8, Alina Costina Luca4, Anca Galaction9.   

Abstract

In the case of SARS-CoV-2 infection, children seem to be less affected than adults, but data regarding epidemiologic characteristics and biochemical values are poor and essentially based on limited case series. The aim of our study is to highlight the predictive value of some biochemical markers at hospitalization, for the correct classification of the patient in the form of disease.
METHODS: We performed an analytical retrospective study on 82 pediatric patients diagnosed with COVID-19 in the emergency department, with moderate or severe form of disease, and treated in our tertiary hospital. We analyzed the epidemiologic characteristics, symptomatology and biochemical values and compare the data according to the form of disease.
RESULTS: The mean age at admission was 4.5 years (median 1 year) and the masculine/feminine ratio was 1.5. Comparing the data between the two groups of patients (42 severe/40 moderate), we observed that the severe form presented with a lower pH at admission (p = 0.02), hyperglycemia (p = 0.01), increased values of transaminases (p = 0.01 and 0.02) and hypoproteinemia (p = 0.01). Also, the severe form was statistically significantly associated with comorbidities, acute respiratory distress, rising of the inflammatory markers during hospitalization. Hyperlactatemia (Lactate > 1.5 mmol/L) was significantly associated with the age under one year (p < 0.001). Mortality rate was 9.75% and the median age at death was 3 months. Univariate logistic regression model shows that the presence of anemia increased the probability of death 88 times, comorbidities 23.3 times and ketoacidosis 16.4 times.
CONCLUSIONS: Metabolic acidosis, hyperlactatemia, hyperglycemia, modified hepatic values and hypoproteinemia are biochemical markers associated with the severe form of disease in SARS-CoV-2 infection in children. Presence of anemia, comorbidities and ketoacidosis are important risk factors for death of pediatric patients with SARS-CoV-2 infection.

Entities:  

Keywords:  SARS-CoV-2 infection; biochemical markers; children; risk factors

Year:  2022        PMID: 35626368      PMCID: PMC9139823          DOI: 10.3390/diagnostics12051213

Source DB:  PubMed          Journal:  Diagnostics (Basel)        ISSN: 2075-4418


1. Introduction

Since January 2020, the COVID-19 pandemic has spread very fast worldwide. Epidemiological, clinical, biochemical data and management applied in different parts of the globe must be carefully analyzed and the results not yet generalized. And this is due to the extraordinary dynamics of the virus as well as the multifactorial influences related to the specifics of each region and the genetic peculiarities of the affected populations. The clinical picture of COVID-19 presents different patterns of presentation in adults and children [1,2]. Although children with COVID-19 infection developed milder forms of the disease than those described in adults, they may have severe complications but a low mortality rate [3]. Severe forms of COVID-19 have been found especially in children with congenital heart disease, some genetic syndromes (e.g. sdr Down), malnutrition, obesity, diabetes and cancer. Although the number of cases of COVID-19 infection in children and adolescents has increased recently, many aspects of the clinical features and prognostic factors remain unclear [3,4]. Early diagnosis, identification of cases requiring hospitalization, risk stratification with timely admission to intensive care units and application of appropriate treatment regimens according to current protocols are key elements for the favorable development of COVID-19 in children [5,6]. Current data on clinical forms and prognostic factors in children and adolescents are relatively limited [4]. COVID-19 is not only a disease with respiratory or digestive manifestations, but a multisystemic disease secondary to the complex interaction between immunological, inflammatory and coagulation cascades [7]. In clinical practice early identification of severe forms of COVID-19 in children is essential for the evolution and prognosis of the disease. In order to predict the evolution of the disease forms from the moment of establishing the diagnosis, the evaluation of some clinical parameters and of some biochemical and immunological markers is absolutely necessary. Which biomarker should be evaluated, when should it be evaluated and what is its usefulness for patient care, are questions that still need to be answered clearly, especially in children? The biochemical markers used in the initial assessment of COVID-19 infections quantify the involvement of various organs or systems, such as: hematological (complete blood count, white blood count (WBC), hemoglobin (Hb), hematocrit (Ht)), inflammation (C reactive protein (CRP), procalcitonin, lactate dehydrogenase ferritin), coagulation (D-dimer levels, fibrinogen, prothrombin time, activated partial thromboplastin time), hepatic values (aspartate aminotransferase (AST), alanine aminotransferase (ALT), bilirubin, albumin), markers of muscle damage (creatine-kinase, myoglobin), renal (serum creatinine), electrolytes, pH [5,6,7,8,9]. The aim of our study is to highlight the predictive value of some biochemical markers at hospitalization, for the correct classification of the patient in the form of disease (moderate or severe). Biochemical markers are valuable for patient management because they can assess the severity or the progression of the disease and can act as risk factors for death.

2. Materials and Methods

We conducted a retrospective analytical study of pediatric patients with SARS-CoV-2 infection treated at our tertiary hospital. Prior to data extraction, approval was granted by the Ethics Committee of “Saint Mary” Emergency Children’s Hospital. The analysis included patients who were tested with the real-time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) test from nasal and pharyngeal swab samples. The determination of a COVID-19 diagnosis was based on the guidelines by the World Health Organization (WHO) [10]. Inclusion criteria for the study consisted of patients who were hospitalized and treated for SARS-CoV-2 infection from March 2020 to February 2022 in our tertiary care center. The exclusion criteria: patients who resulted as negative for the RT-PCR test, asimptomatic patients with SARS-CoV-2 infection or patients with a mild form of the disease. Patient demographic data, symptoms, comorbidities, biochemical markers, length of hospital stay and mortality were extracted from the hospital’s computer database, analyzed and statistically processed. We will further define the terms used in the statistical analysis. To compare the data, we divided patients into two age groups (under one year = infants, and over one year of age = child), and also according to the severity of the disease. The severity of the disease was assessed according to the definition and criteria stated by the National Institute of Health, which we reproduce below literally [11,12]: Moderate illness: Individuals who show evidence of lower respiratory disease during clinical assessment or imaging and who have oxygen saturation (SpO2) ≥ 94% on room air at sea level. Severe illness: Individuals who have SpO2 < 94% on room air at sea level, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) < 300 mm Hg, a respiratory rate >30 breaths/min, or lung infiltrates >50% [11,12].

Statistical Analysis

We initially performed a descriptive statistical process, depending on the form of the disease, the age group and separately for the deceased. We then tried to find whether there was any link or reciprocal influence between the statistical variables mentioned above (demographics, symptoms, comorbidities, biochemical markers, length of hospital stay and mortality) and the severity of the disease or the age of patients with SARS-CoV-2 infection. First of all, the chi-square test and the contingency tables (cross-tabulation) were used in the analysis; the studied variables were of nominal type. Because the analyzed variables are not normally distributed, in the comparisons made between them depending on the form of the disease (severe/moderate) we used the nonparametric Wilcoxon rank-sum and Mann-Whitney tests. Univariate logistic regression was used to determine the risk of death of patients with SARS-CoV-2 infection; the risk was estimated based on independent variables previously validated by the Pearson chi-square test (χ2). In the proposed model, the nominal factor variables were: anemia, comorbidities and ketoacidosis. The dependent variable death is of nominal dichotomous type and can take YES/NO values. All p-values less than 0.05 were considered statistically significant and were double-sided. Data are expressed as median, median absolute deviation (MAD), and minimum and maximum values. All calculations were made using standard statistical package (JASP Team (2022). JASP (Version 0.16.1), University of Amsterdam, Amsterdam, The Netherlands, https://jasp-stats.org/, accessed on 1 April 2022).

3. Results

From a total of 15,879 persons tested in the analyzed period, 1973 were parents and 104 of them were positive for COVID 19 infection. There were 13,906 children tested and 636 were positive for COVID 19 infection; only 82 of them were eligible for our study (diagnosed with moderate or severe form of SARS-CoV-2 infection). This means that 87% of children tested positive for COVID19 were asymptomatic or with mild forms of disease and 13% were with moderate or severe forms. According to the severity of disease, patients were hospitalized in the pediatric ward to which they belonged or in the intensive care unit if the severity of the condition required it. The mean age at admission was 4.5 years (median 1 year); there were 34 patients under the age of 1 (5 neonates) and 48 patients above 1 year old. The male/female ratio was 1.5. Comparing the age, length of hospitalization and biochemical values at admission between the two groups of patients (42 with severe form of the disease and 40 with moderate form) in Table 1 and Table 2, we observed that the severe form presented with a lower pH at admission (U = 619, p = 0.04), hyperglycemia (U = 517, p = 0.02), increased values of transaminases (U = 615, p = 0.036 for ALT and U = 622, p = 0.043 for AST) and hypoproteinemia (U = 204, p = 0.02).
Table 1

Descriptive Statistics depending on the severity of the disease.

ValidMissingMedianMADMinimumMaximum
AgeMODERATE4001.0000.9200.00017.000
Age SEVERE 42 0 2.000 2.000 0.000 17.000
Lenght of HospitMODERATE4005.0002.0001.00016.000
Lenght of Hospit SEVERE 42 0 10.000 2.500 2.000 36.000
LactatemiaMODERATE4002.1000.8000.7004.700
Lactatemia SEVERE 42 0 2.000 0.800 0.500 14.000
pHMODERATE4007.4000.0457.1007.570
pH SEVERE 42 0 7.365 0.100 7.030 7.570
PaO2MODERATE40048.00011.50021.000176.000
PaO 2 SEVERE 42 0 43.000 11.000 17.000 192.000
PaCO2MODERATE40034.5008.50020.00053.000
PaCO2 SEVERE 42 0 39.500 9.500 21.000 97.000
GlycemiaMODERATE40091.0009.00053.000272.000
Glycemia SEVERE 42 0 130.500 49.000 53.000 599.000
HbMODERATE40012.1001.0508.60017.100
Hb SEVERE 42 0 11.350 1.800 6.300 19.400
HtMODERATE40035.6503.05024.00047.710
Ht SEVERE 42 0 34.900 4.200 17.300 46.000
WBCMODERATE40010,385.0004045.0001910.00028,960.000
WBC SEVERE 42 0 8910.000 5140.000 2030.000 30,980.000
PlateletMODERATE400341,500.000104,000.00035,800.000934,000.000
Platelet SEVERE 42 0 280,500.000 94,000.000 13,000.000 786,000.000
CRPMODERATE3912.7602.1100.040118.660
CRP SEVERE 42 0 4.115 3.425 0.000 173.070
ASTMODERATE40020.5006.5006.000176.000
AST SEVERE 42 0 26.500 12.500 8.000 2718.000
ALTMODERATE40029.0008.50013.000113.000
ALT SEVERE 42 0 37.500 18.500 10.000 2724.000
ProteinsMODERATE182260.7852.91545.06073.580
Proteins SEVERE 37 5 55.250 7.650 31.920 75.620
DdimersMODERATE1723762.000577.00034.0004390.000
Ddimers SEVERE 30 12 666.500 474.000 78.000 22,176.000
FerritinMODERATE281288.25046.74023.30010,735.250
Ferritin SEVERE 36 6 132.800 102.720 14.370 3026.650
Table 2

Comparation between the Age, Lenght of hospitalization and biochemical values at admission depending on the severity form of disease Test Statistics.

AgeHospital StayLactatemiapHPaO2PaCO2GlycemiaHbHtWBCPlatelet CountCRPALTASTProteinsDdimers Ferritin
Mann-Whitney U722.000357.000824.500619.000791.500694.000517.000804.500808.500814.000721.500741.500615.000622.000204.000219.000437.000
Wilcoxon W1542.0001177.0001727.5001522.0001694.5001514.0001337.0001707.5001711.5001717.0001624.5001521.5001435.0001442.000907.000372.000843.000
Z−1.098−4.492−0.144−2.052−0.450−1.355−2.997−0.329−0.292−0.241−1.099−0.733−2.088−2.023−2.314−0.797−0.97
Asymp. Sig. (2-tailed)0.2720.0000.8860.0400.6530.1750.0030.7420.7700.8090.2720.4640.0370.0430.0210.4250.365
Exact Sig. (2-tailed)0.2750.0000.8880.0400.6560.1770.0020.7450.7730.8120.2740.4670.0360.0430.0200.4360.371

Grouping Variable: SEVERITY FORM DISEASE.

Also, the severe form was statistically significant associated with comorbidities (χ2 = 17.852, p < 0.001) (Figure 1), acute respiratory distress (χ2 = 9.355, p = 0.002) and longer hospitalization period (U = 357, p < 0.001). We did not find a significant correlation between the severity of the disease and the age group.
Figure 1

Severe form of disease statistically significant associated with comorbidities.

When comparing the two groups of age (infants and child), the results obtained were: fever (χ2 = 5.896, p = 0.02), pneumonia (χ2 = 6.185, p = 0.02) and comorbidities (χ2 = 4.571, p = 0.04) were significantly associated with infants. Regarding the biochemical values, hyperlactatemia (Lactate > 1.5 mmol/L) was significantly associated with the under one year of age group (χ2 = 14.154, p < 0.001); the odds ratio of hyperlactatemia is 8.152 times higher in the age group under one year compared to the child group (Figure 2); high levels of CPR were associated with the child group (χ2 = 4.952, p = 0.04).
Figure 2

Hyperlactatemia significantly associated with the under one year of age group.

The rate of mortality was 9.75% per total (14.7% in the infant group and 6.25% in the child group; not statistically significant), and the median age at death was 3 months. There were 6 boys and 2 girls. The descriptive statistics for the deceased patients is shown in Table 3. We can see that 5 out of 8 children presented with hyperlactataemia and metabolic acidosis. Hyperglicemia, anemia, hypoproteinemia and increased hepatic transaminases were also observed in the majorities of patients.
Table 3

Descriptive statistics for the deceased patients.

SexAge (Years)Days of Hospital.LactatemiapH at AdmisssionPaO2 PaCO2 Glycemia HbHtWBCPlateletCRPALTASTProteins
M7.071.27.5441449810.336.230,980382,00025.43455754.88
M0.37147.2214327539.730.912,749171,0008.5825519335.68
F12.01317.481693013810.934.415,650435,0007.951055949.5
M0.1104.47.185342758.825.428,180370,00021.121119568.23
M0.094.37.24395725114.94629,27013,0000.6812529031.92
M0.222.27.3431532228.425.2203094,0000.4113021745.33
M0.3102.27.3322465998.12530,980548,0002.39655145.03
F5.01817.37753813512.336.16020276,0009.37263265.15
Univariate logistic regression was performed to ascertain the effects of anemia, comorbidities and ketoacidosis on the likelihood that patients dying. The univariate logistic regression model was statistically significant, χ2 = 28.08, p < 0.001 (Table 4).
Table 4

Univariate logistic regression—Model Summary—Death.

Coefficients
Wald Test
EstimateStandard ErrorOdds RatiozWald Statisticdf p
(Intercept)−7.4362.0915.898 × 10−4−3.55612.6451<0.001
Anemia (YES)4.4781.49688.0562.9938.95610.003
Comorbidities (YES)3.1491.46023.3062.1574.65310.031
Ketoacidosis (YES)2.7971.35716.3962.0614.24710.039

Death level ‘YES’ coded as class 1.

The model correctly classified 93.9% of cases. The presence of anemia increased the probability of death 88 times, comorbidities 23.3 times and ketoacidosis 16.4 times. In order to estimate the coefficient of determination as a model summary, we used Nagelkerke’s R-square which shows that all three independent variables contributed 61.4% to the risk of death. Performance Diagnostics: The confusion matrix (Table 5) shows that the 72 true negative and 5 positive cases were predicted by the model. Errors were found in 5 cases (3 cases false negatives and 2 cases false positives).
Table 5

Confusion matrix.

ObservedPredicted
NOYES% Correct
NO72297.297
YES3562.500
Overall % Correct 93.902

The cut-off value is set to 0.5.

4. Discussion

Despite all the protection measures and vaccination programs, the ongoing COVID-19 pandemic poses various challenges for clinicians [6]. From a clinical point of view, SARS-CoV-2 infection can be asymptomatic or may mimic a mild influenza-like illness, but also can evolve to life-threatening complications, even in children. SARS-CoV-2 affects mainly the respiratory tract resulting in pneumonia, but can also affect gastrointestinal, neurological, or cardiovascular systems [13]. In children, the clinical course of COVID-19 is milder than in adults due to trained immunity, vaccination, frequent respiratory infections, better lung regeneration, and lack of comorbidities [6]. Comorbidities, obesity, smoking, alcohol consumption are often associated with adults with an unfavorable course of disease [14]. In our study we found that 87% of children tested positive for COVID19 were asymptomatic or with mild forms of disease and 13% were with moderate or severe forms, which is different from adults, in which 20% of cases are moderate or severe, as reported by WHO [15,16]. A study conducted in China on 2000 pediatric cases found that only 13% of children infected with COVID-19 were symptomatic; a limitation of the study was that ‘infected’ status was not based on laboratory testing, but only on clinical diagnosis [17]. In a systematic review from 2020, 1124 RT-PCR-confirmed cases from 38 studies were analyzed. According to the severity form of the disease, 14.2% patients were asymptomatic, 36.3% with a mild form, 46.0% moderate, 2.1% severe, and 1.2% patients were critical [18]. It should be noted, however, that these patients have sought medical advice and that the severity of the disease and symptoms may be slightly overestimated [19]. Also in consistent with the literature [16], we found a male preponderance of 1.5. While reviews have been published on the management and prognostic factors of SARS-CoV-2 infection in adults [13], recent advancements in novel diagnostic and therapeutic methods justify the need for a more comprehensive synthesis of the current literature, in order to elaborate therapeutic protocols and define risk factors in both adults and children. Patient consultation and clinical evaluation are indispensable and mandatory, but for the accuracy of determining the severity of the disease and the subsequent management of the case, certain biological investigations must be performed. Which biomarker needs to be evaluated, when and in whom, and how best this information can contribute to patient care are questions which currently lack convincing answers [8]. When the anaerobic metabolism of tissues is increased, in infections where there is anemia, fever with increased demand of oxygen, and microvascular obstruction, the value of lactic acid increases as a marker of tissue hypoxia [20]. Changes in biological markers in SARS-CoV-2 infection taken separately are not specific to this disease, but their association may show some specificity. In adults, biochemical markers associated with a severe form of disease are: lymphopenia, neutropenia, elevated serum ALT, AST, LDH, CRP, and ferritin [12,21]. Patients which are critically ill presents with high plasma levels of inflammatory markers, elevated levels of d-dimer and lymphopenia; it is demonstrated that these markers are associated with increased risk of death [13]. We found that metabolic acidosis, hyperlactatemia, hyperglycemia, modified/elevated hepatic values and hypoproteinemia are biochemical markers associated with the severe form of disease in SARS-CoV-2 infection in children; in our study in children, ferritin was not statistically significantly elevated in patients with severe disease. We also found that anemia and ketoacidosis are highly associated with death (increasing the risk of death 88 times and 16.4 times respectively). Therefore, among the biochemical parameters, serum lactate and the presence of metabolic acidosis are useful parameters for appreciating the severity form of illness in children. The value of serum lactate, a parameter of physiological stress and anaerobic metabolism may be recommended in future guidelines to appreciate the COVID-19 severity and the progression of disease. But until now, the value of serum lactate in predicting a severe course in COVID-19 in adults and children is still unclear [22,23]. The first cases of SARS-CoV-2 infection was reported in December 2019; since then there have been over 494 million confirmed cases and 6.1 million deaths reported all around the globe [24]. Elderly patients or those with associated conditions such as cardiovascular disease, obesity, diabetes, chronic respiratory disease, have a more severe course of the disease and a higher risk of death [25]. For children, we demonstrated that the presence of anemia, comorbidities and ketoacidosis are important risk factors for unfavorable evolution of pediatric patients with SARS-CoV-2 infection, and these three independent variables contribute 61.4% to the risk of death. Regarding pediatric patients, general risk factors are represented by certain congenital anomalies such as heart malformations, broncho-pulmonary malformations, malnutrition, low immunodeficiency and age under 3 months [26,27,28]. In our study, the presence of comorbidities increased the risk of death 23.3 times. When comparing the age of our patients, we did not find a significant correlation between the severity of the disease and the age group, but fever, pneumonia and comorbidities were significantly more frequent in the infants group. The rate of mortality was 14.7% for the infant group and 6.25% in the child group, and the median age at death was 3 months; there were 6 boys and 2 girls. Our results are consistent with a multicenter study on 82 institutions across 25 European countries; the study used univariable analysis and found that the most significant factors for requiring intensive care were: age under 1 month, male sex, comorbidities, fever, lower respiratory tract infection, pneumonia or acute respiratory distress syndrome (imagistically diagnosed) and viral co-infection [29]. Although age and concurrent comorbidities of COVID-19 patients largely determine the COVID-19 clinical course, elevated lactate levels may equally facilitate the assessment of disease course. Caterino M and colab. show that is a pathogenic connection between lactic acid and the immune response: high lactate levels being strongly associated with the poor outcome of COVID-19 disease [30]. In terms of recovery, the median duration of hospital stay in adults is 10 to 14 days [31], comparing with 5 days for moderate and 10 days for severe forms in our pediatric cohort study. This difference may again be due to better immunity in children, absence of use of toxic drugs, lower rates of associated abnormalities, and faster recovery.

4.1. Limitations of the Study

There are limitations intrinsic to this study because the review was retrospectively performed and it is a single-center study. The small number of cases in total and especially the small group of patients with unfavorable evolution makes it impossible to extrapolate the results obtained in this study to the entire pediatric population.

4.2. Strengths of the Study

This study is performed on the largest population lot in our country, as our hospital serves the entire northeastern region of Romania. In mid-2020, this region accounted for 18% of Romania’s population, numbering approximately 4 million people. In any case, we cannot generalize the results obtained in this region to our entire country.

5. Conclusions

Metabolic acidosis, hyperlactatemia, hyperglycemia, modified hepatic values and hypoproteinemia are biochemical markers associated with the severe form of disease in SARS-CoV-2 infection in children. When comparing the age of our patients, fever, pneumonia and comorbidities were significantly associated with the infants group. Presence of anemia, comorbidities and ketoacidosis are important risk factors for unfavorable evolution of pediatric patients with SARS-CoV-2 infection. Variations in biochemical values for defining COVID-19 severity or prognosis in children remain an active area of research that may lead to new diagnostic approaches and help us understand disease progression and host responses.
  25 in total

Review 1.  Optimal Nutrition Parameters for Neonates and Infants with Congenital Heart Disease.

Authors:  Alina-Costina Luca; Ingrith Crenguța Miron; Dana Elena Mîndru; Alexandrina Ștefania Curpăn; Ramona Cătălina Stan; Elena Țarcă; Florin-Alexandru Luca; Alexandra Ioana Pădureț
Journal:  Nutrients       Date:  2022-04-17       Impact factor: 6.706

2.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

Review 3.  Biomarkers in COVID-19: An Up-To-Date Review.

Authors:  Madhusudan Samprathi; Muralidharan Jayashree
Journal:  Front Pediatr       Date:  2021-03-30       Impact factor: 3.418

4.  Clinical characteristics of children infected with SARS-CoV-2 in Italy.

Authors:  Isabella Tarissi De Jacobis; Rosa Vona; Alberto Villani; Elisabetta Straface; Camilla Cittadini; Alessandra Marchesi; Laura Cursi; Lucrezia Gambardella
Journal:  Ital J Pediatr       Date:  2021-04-15       Impact factor: 2.638

5.  Management of patients with SARS-CoV-2 infections and of patients with chronic lung diseases during the COVID-19 pandemic (as of 9 May 2020) : Statement of the Austrian Society of Pneumology (ASP).

Authors:  Holger Flick; Britt-Madelaine Arns; Josef Bolitschek; Brigitte Bucher; Katharina Cima; Elisabeth Gingrich; Sabin Handzhiev; Maximilian Hochmair; Fritz Horak; Marco Idzko; Peter Jaksch; Gabor Kovacs; Roland Kropfmüller; Bernd Lamprecht; Judith Löffler-Ragg; Michael Meilinger; Horst Olschewski; Andreas Pfleger; Bernhard Puchner; Christoph Puelacher; Christian Prior; Patricia Rodriguez; Helmut Salzer; Peter Schenk; Otmar Schindler; Ingrid Stelzmüller; Volker Strenger; Helmut Täubl; Matthias Urban; Marlies Wagner; Franz Wimberger; Angela Zacharasiewicz; Ralf Harun Zwick; Ernst Eber
Journal:  Wien Klin Wochenschr       Date:  2020-07       Impact factor: 1.704

6.  Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis.

Authors:  Jing Yang; Ya Zheng; Xi Gou; Ke Pu; Zhaofeng Chen; Qinghong Guo; Rui Ji; Haojia Wang; Yuping Wang; Yongning Zhou
Journal:  Int J Infect Dis       Date:  2020-03-12       Impact factor: 3.623

7.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.

Authors:  Zunyou Wu; Jennifer M McGoogan
Journal:  JAMA       Date:  2020-04-07       Impact factor: 56.272

8.  Clinical Characteristics of Children with Coronavirus Disease 2019 in Hubei, China.

Authors:  Fang Zheng; Chun Liao; Qi-Hong Fan; Hong-Bo Chen; Xue-Gong Zhao; Zhong-Guo Xie; Xi-Lin Li; Chun-Xi Chen; Xiao-Xia Lu; Zhi-Sheng Liu; Wei Lu; Chun-Bao Chen; Rong Jiao; Ai-Ming Zhang; Jin-Tang Wang; Xi-Wei Ding; Yao-Guang Zeng; Li-Ping Cheng; Qing-Feng Huang; Jiang Wu; Xi-Chang Luo; Zhu-Jun Wang; Yan-Yan Zhong; Yan Bai; Xiao-Yan Wu; Run-Ming Jin
Journal:  Curr Med Sci       Date:  2020-03-24

Review 9.  Coronavirus global pandemic: An overview of current findings among pediatric patients.

Authors:  Evanthia Perikleous; Aggelos Tsalkidis; Andrew Bush; Emmanouil Paraskakis
Journal:  Pediatr Pulmonol       Date:  2020-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.